Xingyu Mu
Guangxi Medical University(CN)Guilin Medical University(CN)Sichuan University(CN)West China Medical Center of Sichuan University(CN)West China Hospital of Sichuan University(CN)Beijing Shijitan Hospital(CN)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Immune cells in cancer, Renal cell carcinoma treatment, Epigenetics and DNA Methylation
Most-Cited Works
- → FTO modifies the m6A level of MALAT and promotes bladder cancer progression(2021)170 cited
- → RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment(2019)60 cited
- → Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis(2023)55 cited
- ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation.(2018)
- → Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis(2021)52 cited
- → Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy(2018)43 cited